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 The equine CD1d has a suitable pocket for α-GalCer ligation. 3 
 α-GalCer failed to stimulate equine NKT cells in vitro or in vivo. 4 
 α-GalCer loaded tetramers did not bind equine cells. 5 
 α-GalCer is an unsuitable adjuvant in horses. 6 





α-GalCer is a potent immunomodulatory molecule that is presented to NKT cells 12 
via the CD1 antigen-presenting system. We hypothesized that when used as an 13 
adjuvant α-GalCer would induce protective immune responses against Rhodococcus 14 
equi, an important pathogen of young horses. Here we demonstrate that the equine 15 
CD1d molecule shares most features found in CD1d from other species and has a 16 
suitable lipid binding groove for presenting glycolipids to NKT cells. However, equine 17 
CTL stimulated with α-GalCer failed to kill cells infected with R. equi and α-GalCer did 18 
not increase killing by CTL co-stimulated with R. equi antigen. Likewise, α-GalCer did 19 
not induce the lymphoproliferation of equine PBMC or increase the proliferation of R. 20 
equi-stimulated cells. Intradermal injection of α-GalCer in horses did not increase the 21 
recruitment of lymphocytes or cytokine production. Furthermore, α-GalCer–loaded 22 
CD1d tetramers, which have been shown to be broadly cross-reactive, did not bind 23 
equine lymphocytes. Altogether, our results demonstrate that in contrast to previously 24 
described species, horses are unable to respond to α-GalCer. This raises questions 25 
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about the capabilities and function of NKT cells and other lipid-specific T lymphocytes in 1 
horses.  2 





Rhodococcus equi 8 
  9 
  10 
Page 3 of 37
4 
 
1. Introduction 1 
Natural killer T (NKT) cells, are a subset of novel T lymphocytes that have 2 
characteristics of classic activated or memory T cells, and express the NK 1.1 marker 3 
(Makino et al., 1995). These cells share features of both the innate and adaptive 4 
immune systems (Brennan et al., 2013). NKT cells are found in the circulation and 5 
tissues in a primed stage (memory phenotype) that does not require prior contact with 6 
foreign antigen (de Lalla et al., 2008). Upon activation, NKT cells rapidly release 7 
significant amounts of both T helper type 1 (Th1) and Th2 cytokines. Although NKT cells 8 
are mostly CD4+ or CD4-CD8- (double negative) and can serve as helper cells, they can 9 
also exert potent cytotoxic effects (Gapin et al., 2001; Kawano et al., 1998; Metelitsa et 10 
al., 2001).  11 
In contrast to classical T lymphocytes, which recognize antigens presented via 12 
MHC molecules, NKT cells are CD1d-restricted (Bendelac et al., 1995). CD1d is a 13 
member of the CD1 family, a group of non-polymorphic MHC class I-like surface 14 
glycoproteins that contain a hydrophobic binding groove and are specialized in their 15 
ability to present lipid-based antigens to T cells (Moody et al., 2005). The CD1d gene is 16 
broadly conserved across species, and is found in all mammals studied so far with the  17 
exception of marsupials (Baker and Miller, 2007).  18 
A wide variety of natural exogenous ligands have been shown to bind CD1d and 19 
then activate NKT cells (Fischer et al., 2004; Kinjo et al., 2011; Kinjo et al., 2006; Kinjo 20 
et al., 2005). However, most studies with NKT cells are performed with a synthetic 21 
analogue of a glycolipid originally derived from the marine sponge Agelas mauritianus, 22 
α-galactosylceramide (α-GalCer). This molecule contains a saturated C26 fatty acyl 23 
chain and a C18 phytosphingosine base (Kawano et al., 1997). In numerous species, 24 
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including humans (Spada et al., 1998), pigs (Thierry et al., 2012), rats (Monzon-1 
Casanova et al., 2010), and mice (Kawano et al., 1997), α-GalCer binds CD1d 2 
molecules and is presented to specialized invariant NKT cells (iNKT cells, also called 3 
Type 1 NKT cells) that recognize the glycolipid via a highly conserved T cell receptor 4 
(TCR) α-chain (Borg et al., 2007). As a result, α-GalCer acts as a strong NKT cell 5 
agonist. In mice, a single injection of α-GalCer can activate the NKT cell population, 6 
stimulating the immediate release of cytokines including IFN-γ, IL-4, TNF, IL-2, and IL-7 
10 (Fujii et al., 2003; Nishimura et al., 2000; Reilly et al., 2012). These cytokines 8 
simultaneously activate other cells including classic T cells, NK cells, monocytes, and B 9 
cells.  This leads to the production of more cytokines and chemokines, giving α-10 
GalCer/NKT cells a potent immunomodulatory capacity (Subrahmanyam and Webb, 11 
2012).  12 
The capacity of NKT cells to regulate the immune response has been shown to 13 
improve the outcome of numerous vaccines (Chackerian et al., 2002; Gonzalez-14 
Aseguinolaza et al., 2002; Huang et al., 2008; Sada-Ovalle et al., 2010). In these 15 
experiments, α-GalCer acts as an effective vaccine adjuvant by modulating cytokine 16 
levels, boosting cytotoxic T lymphocyte (CTL) and humoral responses, as well as 17 
enhancing antigen presentation by dendritic cells. A recent study in mice showed that 18 
immunization with Mycobacterium bovis bacillus Calmette-Guerin (BCG) with α-GalCer 19 
incorporated into its membrane increased protection against challenge with virulent M. 20 
tuberculosis when compared to immunization with unmodified BCG (no α-GalCer) 21 
(Venkataswamy et al., 2009). 22 
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The presence of NKT cells in horses and their ability to recognize α-GalCer 1 
remains unknown. However, recent work in our laboratory identified an equine CD1 2 
cluster that is composed of 13 genes (Dossa et al., 2014). This cluster includes a CD1d 3 
homologue that is expressed in several antigen-presenting cells (APC), including 4 
macrophages and dendritic cells. Additionally, previous work in another lab indicated 5 
that horses possess a TCR α-chain that is homologous to the highly conserved TCR 6 
used by human and murine iNKT cells (Looringh van Beeck et al., 2009). This equine 7 
TCR was predicted to interact with equine CD1d. Together these findings strongly 8 
suggest that the CD1d/NKT cell system is present in horses. 9 
Little is also known about the specific roles played by CD1, the lipid antigen 10 
presentation system, or NKT cells in horses. Evidence suggests that immune responses 11 
to microbial lipids are essential in the protection against Rhodococcus equi, an 12 
important equine pathogen (Vázquez-Boland et al., 2013). R. equi is a nocardioform 13 
actinomycete bacterium that is closely related and structurally similar to M. tuberculosis 14 
(Rahman et al., 2003). Whereas M. tuberculosis causes tuberculosis in humans, R. equi 15 
causes pyogranulomatous pneumonia in horses between 2-5 months of age. 16 
Rhodococcal pneumonia is a common cause of morbidity and mortality in young horses 17 
worldwide. As a result of exposure early in life, adult horses are almost invariably 18 
immune. Furthermore, immune adult horses have CTL that lyse R. equi infected cells in 19 
an MHC class-I unrestricted fashion (Patton et al., 2004; Patton et al., 2005). These 20 
CTL recognize unique R. equi lipids, presumably presented by the CD1 system (Harris 21 
et al., 2010). 22 
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Despite the observation that naturally developing adaptive immune responses 1 
strongly protect adult horses, efforts to develop a vaccine to prevent rhodococcal 2 
pneumonia in foals have been unsuccessful (Lopez et al., 2003; Lopez et al., 2008; 3 
Mealey et al., 2007). The need to stimulate protective cell-mediated responses in the 4 
first weeks of life is likely a critical barrier. Considering that horses express a CD1d 5 
molecule and carry at least one apparent NKT cell TCR homologue, we hypothesized 6 
that the glycolipid α-GalCer would stimulate equine NKT cells and consequently 7 
enhance the immunogenicity of an R. equi vaccine. In this study, we demonstrate that 8 
molecular models predict that the equine CD1d (eqCD1) binding groove site will 9 
accommodate and bind α-GalCer. However, we were unable to demonstrate an 10 
immunomodulatory effect in vitro or in vivo, suggesting important differences between 11 
horses and previously studied mammals.   12 
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2. Material and methods 1 
2.1 Construction of an eqCD1d Binding Domain Homology Model 2 
 To determine the evolutionary relationship between equine CD1d (eqCD1d) and 3 
CD1d from other species, an alignment of the CD1d binding domain was performed 4 
using ClustalW. Subsequently, a phylogenetic analysis based on a neighbor joining tree 5 
was created using MEGAv5.2 software (http://www.megasoftware.net) (Supplementary 6 
Fig. 1).  7 
A high quality model of the binding domain of the eqCD1d molecule was 8 
generated using a previously described multiple template homology model protocol and 9 
X-ray crystal structure data available for different species of CD1d bound to α-GalCer 10 
(Garzón et al., 2009) (Supplementary Fig. 2A, B). The detailed methodology used is 11 
provided in Supplementary Material and Methods.  12 
 13 
2.2 Horses 14 
Adult horses of various breeds were used in accordance with the Washington 15 
State University institutional animal care and use committee. Venous blood was 16 
collected from the jugular vein of each horse using evacuated containers (Baxter, 17 
Deerfield, IL) containing 16% anticoagulant citrate dextrose A (ACD; Baxter). Peripheral 18 
blood mononuclear cells (PBMC) were isolated from venous blood using a Ficoll-19 
Hypaque technique (Zhang et al., 1998).  20 
 21 
2.3 Bacteria 22 
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The plasmid-bearing virulent R. equi strain ATCC 33701 bacteria were grown in 1 
brain heart infusion broth (BHI; Becton Dickinson, Franklin Lakes, NJ), overnight at 2 
37oC with shaking for 8h. After the 8h growth, the number of bacteria per ml was 3 
estimated with an optical density reading of 0.050 Å at 600 nm (Beckman DU-64) 4 
equaling 1.5 × 108 R. equi per ml. The bacterial concentration was confirmed by plating 5 
serial dilutions on BHI plates and calculating the colony-forming units per ml.   6 
2.4 Lipids  7 
The synthetic glycolipids α-GalCer (KRN7000) and 7DW8-5 were purchased 8 
from Avanti Polar Lipids, Alabaster, AL and Diagnocine, Hackensack, NJ. The 9 
remaining synthetic lipids were synthesized by one of the investigators (PJJ) at the 10 
School of Biosciences, University of Birmingham (Birmingham, UK), using modified 11 
procedures to those described previously (Jervis et al., 2011; Jervis et al., 2010). 12 
R. equi lipids were isolated using a previously described chloroform/methanol 13 
extraction method (Harris et al. 2010). After overnight separation in a separatory funnel, 14 
the organic layer was collected and dried on a rotary evaporator at 37°C. The sample 15 
was then resuspended in PBS, with sonication to a concentration of 10µg/ml. 16 
 17 
2.5 Cytotoxicity assay 18 
 CTL assays were performed using previously published methods (Harris et al., 19 
2010; Patton et al., 2004). Briefly, effector cells were derived by stimulating equine 20 
PBMC with one of the following for 5 days at 37oC with 5% CO2: (i) 100ng/ml of α-21 
GalCer, (ii) 6 × 106 R. equi ATCC 33701/ml (multiplicity of infection in monocytes 22 
approximately 0.3), or (iii) 6 × 106 R. equi ATCC 33701/ml plus 100ng/ml of α-GalCer. 23 
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Effectors were then rested for 2 days without antigenic stimulation prior to testing in the 1 
CTL assay. Target cells were obtained by eluting adherent peripheral blood adherent 2 
cells (PBAC) from MHC class I matched or mismatched horse. The effector cells were 3 
then added to target cells previously labeled with 51Cr per ml (PerkinElmer, Waltham, 4 
MA). Target cells had been (i) pulsed with 100ng/ml α-GalCer, (ii) infected with 5 × 105 5 
live R. equi, (iii) infected with 5 × 105 live R. equi and pulsed with 1µg/ml α-GalCer, or 6 
(iv) pulsed with media containing only control vehicle (0.1% DMSO). Specific lysis was 7 
calculated using the formula [(E – S)/(T – S)] × 100, where E is the mean of three test 8 
wells, S is the mean spontaneous release from three target cell wells without effector 9 
cells, and T is the mean total release from three target cell wells with 2% Triton X-100 10 
(Sigma-Aldrich). As previously described, significant lysis was defined as 3 standard 11 
errors above the negative control value. Cytotoxic assay results shown are a 12 
representative example of three animals analyzed in three independent experiments 13 
performed in triplicate. 14 
 15 
2.6 Lymphoproliferation assays 16 
Equine PBMC were plated in 96-well plates at a density of 2.5 × 105 cells/well in 17 
100µl of complete medium. Each well was either (i) pulsed with 100ng/ml α-GalCer, (ii) 18 
infected with 2.5 × 105 live R. equi/ml, (iii) infected with 2.5 × 105 live R. equi/ml and 19 
pulsed with 100ng/ml α-GalCer, (iv) pulsed with 10µg/ml R. equi lipid (v) pulsed with 20 
10µg/ml R. equi lipid and 100ng/ml α-GalCer, (vi) pulsed with 10U/ml human IL-2 as 21 
positive control, or (vii) pulsed with media only containing control vehicle (0.1% DMSO). 22 
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One hour post R. equi infection, 20 µl of complete medium containing 0.05 mg/ml 1 
gentamicin sulfate was added to each culture well to kill extracellular bacteria. The 2 
plates were then cultured at 37oC with 5% CO2 for 72h. [3H] thymidine was added at 3 
0.5μCi/well 18h prior to the termination of culture. Cells were harvested on an 4 
automated 96-well plate harvester (TomTec Inc., Orange, CT) and [3H] Thymidine 5 
uptake was measured by liquid scintillation spectroscopy (Wallac Inc., Gaithersburg, 6 
MD). Splenocytes from Swiss Webster mouse were isolated as described previously 7 
(Sakai et al., 1999), plated into 96-well plates and used as described for equine cells to 8 
serve as a positive control. All assays were performed in triplicate. Cells from four 9 
animals were analyzed in four independent experiments. In subsequent experiments, 10 
the assay was repeated using variants of α-GalCer (100ng/ml) with shorter fatty acyl 11 
chains (C8, C12, C16, or C20) and with other previously described or putative NKT cell 12 
agonists (See Table 1). The α-GalCer analogue (GalNHAc C20:2), where the hydroxyl 13 
group at the 2-position of the galactose head-group was removed, was used as an 14 
additional negative control. This hydroxyl group is crucial to the activation of murine and 15 
human NKT cells (Jervis et al., 2012). R. equi lipid antigens (10µg/ml) were used as 16 
positive control.   17 
 18 
2.7 Intradermal testing 19 
To measure in vivo cell-mediated immune responses, a previously described 20 
intradermal injection and biopsy method was used with modifications (Liu et al., 2012). 21 
Prior to injections, a rectangular area on the neck of three horses was clipped and 22 
Page 11 of 37
12 
 
scrubbed with betadine and alcohol. Intradermal injections consisted of 0.2ml PBS 1 
containing the following: (i) 400µg α-GalCer, (ii) 109 heat-killed R. equi, (iii) 109 heat-2 
killed R. equi with 400µg α-GalCer, or (iv) 400µg R. equi lipids. Saline alone containing 3 
control vehicle (0.1% DMSO) was also injected as the negative control. After 48h, a 4 
2mm skin biopsy from each injection site was collected and stored in RNALater 5 
(Ambion, Austin, TX) at 4oC. An additional 4mm skin biopsy sample was placed in 10% 6 
formalin for subsequent histopathology. 7 
 8 
2.8 Histopathology of skin biopsies 9 
Serial 6µm sections were cut from 4mm skin biopsy samples using a Leica 10 
RM2235 Microtome and placed onto poly-L-lysine-coated glass slides for hematoxylin 11 
and eosin (H&E) staining. H&E staining was performed according to established 12 
protocols (Fischer et al., 2008). All slides were read by a board certified veterinary 13 
pathologist (SAH). 14 
 15 
2.9 Quantitative Real-Time PCR 16 
The 2mm skin biopsies stored in RNALater were submitted to Dr. David W. 17 
Horohov, Laboratory of Equine Immunology, Maxwell H. Gluck Equine Research 18 
Center, University of Kentucky (Lexington, KY). Relative quantity (RQ) of gene 19 
expression for every sample was assessed by real-time PCR and 2-ΔΔCT method, 20 
following previously established protocols (Liu et al., 2012). RQ data were natural log 21 
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transformed to satisfy the assumption of normality. Statistical analyses were performed 1 
using SAS software. Results were expressed as log transformed means ± SEM. Mean 2 
differences between treatment groups were evaluated using Fisher’s least significant 3 
difference (LSD) test. A p value < 0.05 was considered significant. 4 
 5 
2.10 Flow cytometric analysis – CD1d tetramers 6 
Equine PBMC and murine splenocytes were plated in 75cm2 flasks at 4 × 106 7 
cells/ml, in 25ml of complete media containing 10U/ml of IL-2 and were stimulated for 0 8 
or 5 days with and without 100ng/ml α-GalCer. Before and after stimulation, cells were 9 
stained with human or mouse CD1d:Alexa647 tetramers at 1ug/ml, either loaded with α-10 
GalCer or empty (unloaded). The tetramers were generously provided by the National 11 
Institutes of Health Tetramer Facility (Atlanta, GA). Briefly, 106 equine and murine 12 
cells/well were plated in 96-well plates in the respective cocktails containing the 13 
species-specific anti-CD3 monoclonal antibodies and CD1d-tetramers diluted in PBS. 14 
After 1 hour of incubation, cells were washed and fixed. Data were collected using a 15 
FACSort flow cytometer. At least 1 × 106 viable cell events were acquired in the 16 
peripheral blood lymphocyte gate using Cell Quest software (Becton Dickinson). Results 17 
were analyzed using FCS Express software (De Novo Software, Thornton, Ontario, 18 
Canada) and FlowJo software (FlowJo, Ashland, OR). Positive staining was determined 19 
by comparing loaded and empty CD1d tetramers.  20 
 21 
  22 
Page 13 of 37
14 
 
3. Results 1 
3.1 Equine CD1d molecular structure – comparison to other species 2 
Phylogenetic analysis of the eqCD1d binding domain found that eqCD1d was 3 
more closely related to huCD1d than any of the other species analyzed (Supplementary 4 
Fig. 1), providing evidence of evolutionary proximity and suggesting functional 5 
similarities.  6 
The high quality eqCD1d molecular model demonstrated that most structural 7 
features of previously described CD1d molecules are conserved in horses. However, 8 
some characteristics unique to equine CD1d were also apparent. The total volume of 9 
the binding cavity of eqCD1d was 1040 Å3. By comparison, the volume of the binding 10 
cavities for the reference CD1d molecules were: huCD1d 1009 Å3, boCD1d 985 Å3 and 11 
muCD1d 856 Å3 (Fig. 1A-D). The CD1d antigen/ligand binding cavity is composed of 12 
two pockets, F’ and A’. The F’ pocket of CD1d has been described as rather shallow, 13 
resulting in a more closed entrance when compared to the other members of the CD1 14 
family. This shallowness is due to the formation of an F’ roof between the carboxy-15 
terminal end of the α1 helix and the amino-terminal end of the α2 helix. In eqCD1d this 16 
groove seems to be slightly larger than in previously described CD1d molecules 17 
(Supplementary Fig. 3A). The volume calculated for the equine CD1d F’ pocket (489 Å3) 18 
is 12% greater than in huCD1d, 9% greater than in boCD1d and 15% greater than in 19 
muCD1d. The predicted eqCD1d F’ pocket entrance is also wider. This is due to the 20 
presence of small hydrophobic residues in place of bulkier side chains, such as the 21 
Leu/Ile96Val, Leu/Ile98Val, Phe116Ala, and Phe77Val replacements. Amino acids at 22 
positions 96, 98 and 114 have been shown to be critical to structure and function 23 
because these residues form the floor of the F’ pocket (Supplementary Fig. 3B). As a 24 
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result of these substitutions, the F’ pocket of eqCD1d appears to be deeper than the 1 
CD1d F’ pocket in other species. 2 
In most members of the CD1 family the A’ pocket consists of a rounded “donut-3 
like” tunnel that lies under the amino-terminal side of α1 (and hence carboxy-terminal 4 
side of α2). The “donut” is formed by a vertical “pole” produced by two conserved 5 
residues, Phe70 on the roof of the pocket and Val12 on the floor. In CD1d isoforms, 6 
however, the conserved residue Val12 is replaced by Cys12, resulting in a partially 7 
transected tunnel. The model predicted that this feature is conserved in eqCD1d 8 
(Supplementary Fig. 3C, D). Similar to other species, the modelled A’ pocket of eqCD1d 9 
forms on the side of the F’ pocket, wraps 360° around the A’ pole, and connected back 10 
to the F’ pocket. Bovine CD1d is unique because a Cys166Phe substitution truncates 11 
the pocket under α2. This substitution, which limits the size of ligands that the binding 12 
cavity can accommodate, is not present in human, murine, or in equine CD1d.  13 
Finally, “portals” have been proposed to exist in some CD1 isoforms as a means 14 
to accommodate the long lipid tails of ligands whose volume would otherwise exceed 15 
that of the cavity. For example, in huCD1b, the so-called C’ portal exists at the side of 16 
the F’ pocket, underneath the α2 link. In huCD1c the D’ portal opens up the cavity on 17 
the side of the A’ pocket. No such portals are predicted in eqCD1d. However, our model 18 
of eqCD1d predicts the presence of a novel tunnel/portal at the amino-terminal side α1 19 
of the A’ pocket. We have putatively named this the “g’ tunnel/portal” (Supplementary 20 
Fig. 3E). Structurally, the proposed g’ portal is an extension of the A’ pocket. It appears 21 
to result from the replacement of bulky side chains that close the A’ pocket in other CD1 22 
isomorphs. In eqCD1, a Cys at position 63 together with the His38Tyr substitution leads 23 
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to formation of the putative tunnel. The tunnel is further formed by a Val (huCD1d)/47Ile 1 
substitution at the bottom of the pocket and the conserved Leu66 at the top of the 2 
pocket. As a result of its strong interaction with 46Ile, Gln67 seems to have a stabilizing 3 
effect comparable with the disulfide bridge that maintains the C’ portal in CD1b. 4 
Stabilization of the tunnel aperture allows for connection to the exterior face of the 5 
binding domain (Supplementary Fig. 3F). 6 
 7 
3.2 Binding model: eqCD1d in complex with α-GalCer 8 
A primary goal of our modeling work was to make predictions regarding the ability 9 
of eqCD1d to bind and present α-GalCer, and to characterize the predicted interactions. 10 
Briefly, the different α-GalCer molecules previously co-crystallized with huCD1d, 11 
boCD1d and muCD1d were easily placed in the same orientation when inserted into the 12 
eqCD1d model (Fig. 1E-G). There were no steric clashes between the acyl chains and 13 
the surface of the modeled cavity, further supporting the hypothesis that equine CD1d 14 
should be able to effectively bind α-GalCer. 15 
 To evaluate the conservation of key residues of eqCD1d that are not part of the 16 
binding cavity but are likely to interact with the α-GalCer head-group or the NTK cell 17 
receptor, we aligned eqCD1d with huCD1d, boCD1d and muCD1d (Supplementary Fig. 18 
4). These amino acids are likely essential for the correct presentation of α-GalCer and 19 
recognition of the CD1d/α-GalCer complex by NKT cells. Among the residues in the 20 
CD1d side chains that interact with the sugar head-group of the α-GalCer ligand 21 
(huCD1d: Asp80, Asp151, and Trp153 and muCD1d: Asp80, Asp153, and Trp156), all 22 
were conserved in eqCD1d (Borg et al., 2007; Koch et al., 2005). Among the 11 CD1d 23 
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residues known to mediate direct contact of CD1d/α-GalCer with the NTK T cell 1 
receptor, two amino acids (huCD1d: Arg89 Gln150 and muCD1d: Ser89 Asn150) are 2 
replaced (with His89 and Asp150) in eqCD1d (Borg et al., 2007).  3 
 4 
3.3 The effects of α-GalCer on equine CTL  5 
Previous work in our lab demonstrated that the age-associated acquisition of 6 
protective immune responses against R. equi in horses correlates with the development 7 
of R. equi-specific CTL. In other species, α-GalCer can act as a potent adjuvant for 8 
priming and boosting CTL response. In this study, we first investigated the ability of α-9 
GalCer alone to stimulate equine CTL. As expected, effector cells stimulated with R. 10 
equi produced significant killing of R. equi-infected cells but did not kill uninfected cells 11 
or cells pulsed with α-GalCer. In contrast, cells stimulated with α-GalCer failed to kill R. 12 
equi-infected or uninfected cells, and they also failed to kill cells pulsed with α-GalCer 13 
(Fig. 2A). MHC-class I matched target cells and target cells pulsed with higher and 14 
lower concentrations of α-GalCer (1ng/ml to 5µg/ml) were also tested and demonstrated 15 
similar results (data not shown). 16 
To investigate if α-GalCer could enhance the cytotoxic activity of R. equi-specific 17 
CTL, effector cells were concomitantly stimulated with R. equi and α-GalCer and 18 
compared with cells stimulated with R. equi only. R. equi-stimulated cells were able to 19 
kill infected targets, and this specific killing increased with an increase in the 20 
effector:target cell (E:T) ratio. The effector cells that were concomitantly stimulated with 21 
R. equi and α-GalCer were also able to kill infected targets, and the specific killing 22 
increased with an increase in the E:T ratio. However α-GalCer did not enhance R. equi-23 
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specific CTL activity. There was no significant α-GalCer-associated increase in the 1 
killing of infected cells at any E:T ratio (Fig. 2B). Additional stimulation time points (from 2 
24h up to 10 days) and higher and lower concentrations of α-GalCer (1ng/ml to 5µg/ml) 3 
were also tested and demonstrated similar results (data not shown). 4 
 5 
3.4 The effects of α-GalCer on proliferation of equine PBMC 6 
In other species, even small amounts of α-GalCer are able to activate the entire 7 
NKT cell population. To investigate the capacity of α-GalCer to stimulate lymphocyte 8 
proliferation in horses, equine PBMC were pulsed with α-GalCer and cell proliferation 9 
measured after 72 hours. Murine cells served as positive controls. After the incubation 10 
period, murine cells (which are known to be activated by α-GalCer), demonstrated a 11 
significant proliferative response (data not shown, but this response is shown in Fig. 5, 12 
Section 3.7 – below). In contrast to murine cells, α-GalCer had no significant effect on 13 
equine cells (Fig. 2C). Additional stimulation time points (from 24h to 7 days) and higher 14 
and lower concentrations of α-GalCer (1ng/ml to 5µg/ml) were also tested and 15 
demonstrated similar results (data not shown).  16 
To assess the capacity of α-GalCer to act as an immunostimulatory molecule that 17 
could enhance the proliferation of equine lymphocyte when co-administrated with R. 18 
equi antigen, equine cells were concomitantly pulsed with α-GalCer and R. equi lipid 19 
antigens or concomitantly pulsed with α-GalCer and infected with live R. equi. These 20 
were compared with cells infected with live R. equi or stimulated with R. equi lipid 21 
antigen alone. After 72h of incubation, proliferation was measured and demonstrated 22 
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that both live R. equi and R. equi lipids were able to stimulate equine cells; however, α-1 
GalCer did not significantly increase the lymphoproliferative effect when co-2 
administrated with either live R. equi or R. equi lipid antigens (Fig. 2C). 3 
 4 
3.5 In vivo equine immune responses to α-GalCer 5 
Because of α-GalCer’s capacity to trigger a strong immune response in other 6 
species, this glycolipid has been tested as an adjuvant for several vaccines. Perhaps 7 
our in vitro systems are lacking a key component that is nonetheless present in vivo. To 8 
investigate if α-GalCer would also have an adjuvant/immunostimulatory effect in horses, 9 
a group of three animals were randomly selected to test the effects of α-GalCer in vivo. 10 
As expected, intradermal injection of heat-killed R. equi bacteria induced intense 11 
dermatitis that was characterized by perivascular lymphocyte accumulations and 12 
multifocal accumulation of neutrophils. Injection of R. equi lipid antigen induced a similar 13 
but less severe inflammatory response. The skin from sites injected with saline 14 
(negative control) were within normal limits. Biopsies from skin injected with α-GalCer 15 
alone were mostly indistinguishable from the negative control except for some 16 
occasional very mild perivascular accumulations of lymphocytes in the deep dermis. 17 
The addition of α-GalCer to R. equi antigen did not produce detectable increases in the 18 
local tissue response (Supplementary Fig. 5).  19 
Quantitative real-time PCR performed on mRNA extracted from skin biopsies 20 
demonstrated that heat-killed R. equi was able to significantly increase the recruitment 21 
of CD4, CD8 and CD86 positive cells to the site of injection (Fig. 3). Likewise, there was 22 
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an increase in mRNA encoding perforin and granzyme. Heat-killed R. equi also 1 
increased local transcription of the cytokines IFN-γ, IL-12, and IL-4. No increase in the 2 
transcript of IL-6 was detected. Although not as potent as heat-killed bacteria, R. equi 3 
lipid antigens were also able to significantly increase the recruitment of CD4, CD8 and 4 
CD86 positive cells to the site of injection and increase the number of transcripts for 5 
IFN-γ, granzyme, and perforin. However, there was no significant increase in 6 
transcription of IL-12, IL-4 or IL-6. Under the conditions of our experiment, α-GalCer 7 
alone was unable to significantly increase the recruitment of any cell marker, nor did it 8 
increase the production of any cytokine investigated. Additionally, there was no 9 
significant increase in any cell surface marker or cytokine production when α-GalCer 10 
was co-injected with heat-killed R. equi. Small changes in some cytokines and markers 11 
were not statistically significant. A small increase in the production of IL-12 was 12 
observed when α-GalCer was co-injected, but was not statistically significant (Fig. 3). 13 
 14 
3.6 The recognition of equine NKT cells by CD1d-tetramers  15 
The capacity of human CD1d (huCD1d) to present α-GalCer to murine NKT cells 16 
and vice versa demonstrates the strong conservation of the NKT cell – CD1d interaction 17 
between species. Likewise, human and murine CD1d (muCD1d) tetramers loaded with 18 
α-GalCer bind NKT cells from both species, whereas empty (unloaded) tetramers bind 19 
neither. Investigators have successfully used murine CD1d-αGalCer tetramers as a tool 20 
to unequivocally identify an NKT cell population in pigs (Thierry et al., 2012). Therefore, 21 
we tested human and muCD1d tetramers binding to equine cells to look for a similar 22 
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cross-reactive NKT cell population in horses. Briefly, equine PBMC were stained with 1 
tetramers and species-specific anti-CD3 monoclonal antibody at the day of cell 2 
collection (Day 0). Murine cells were used as positive controls. A second population of 3 
PMBC from the same cell collection was studied after being stimulated for 5 days with 4 
α-GalCer to expand NKT cells. Gating on viable leukocytes demonstrated that both 5 
human and murine α-GalCer loaded-CD1d-tetramers bound a subpopulation of CD3 6 
positive murine cells. As previously demonstrated, empty tetramers (no α-GalCer) did 7 
not bind. After 5 days of stimulation with α-GalCer, the number of murine cells positive 8 
for α-GalCer loaded-tetramers significantly increased, when compared with cells from 9 
Day 0 or with unstimulated cells. However, we were unable to detect tetramer-positive 10 
cells among the equine CD3 population. Neither α-GalCer-loaded-human CD1d-11 
tetramers nor α-GalCer-loaded-mouse CD1d- tetramers reacted with equine cells. 12 
There was no significant staining of equine cells after 5 days of stimulation with α-13 
GalCer, i.e. no tetramer-positive cells were detected among the equine CD3 positive 14 
cells after an attempt to expand α-GalCer-reactive cells, as previously demonstrated 15 
with murine cells (Fig. 4).  16 
3.7 The effects of α-GalCer analogues and other NKT cell agonists on equine 17 
PBMC 18 
The bovine CD1d homologue has a shallow antigen-binding pocket compared to 19 
other species and consequently cannot accommodate the 26-carbon fatty acyl chain of 20 
α-GalCer. Thus full-length α-GalCer does not bind bovine CD1d and does not activate 21 
bovine NKT cells (Wang et al., 2012). However, bovine CD1d is able to bind and 22 
present shorter α-GalCer analogues that contain a C12 or C16 fatty acyl chain (Nguyen 23 
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et al., 2013). To explore whether pocket size or conformation might also affect α-GalCer 1 
presentation in horses, α-GalCer with shorter acyl chains containing C8, C12, C16 and 2 
C20 were produced and their capacity to induce the proliferation of equine lymphocytes 3 
was tested. Murine cells, which are known to be activated by α-GalCer, were used as a 4 
control – i.e. to confirm that the synthetic lipids were biologically active. After 72h of 5 
incubation, all α-GalCer variants were able to stimulate the proliferation of murine 6 
lymphocytes. In contrast, none of the short chain analogues induced proliferation of 7 
equine cells (Fig 5A).  8 
To determine whether other human or murine NKT cell agonists might bind to 9 
equine CD1d and activate equine NKT cells, 9 additional lipid compounds were 10 
synthesized and tested (Table 1). The specific chemical structures of these lipids are 11 
shown in Supplementary Fig. 6. Murine cells demonstrated a significant proliferative 12 
response to all nine NKT cell agonists tested (Fig. 5B). Murine cells did not proliferate in 13 
response to the negative control that lacked a hydroxyl group at the 2-position of the 14 
galactose head group, demonstrating the NKT cell specificity of the assay. As expected, 15 
R. equi lipids stimulated strong proliferative responses when added to equine PBMC. 16 
However, none of the NKT cell agonists were able to induce proliferation of equine cells.  17 
18 
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4. Discussion 1 
 R. equi is a soil-borne organism that is ubiquitous in equine environments and an 2 
important cause of morbidity and mortality in young horses. Virtually all foals are 3 
exposed to R. equi shortly after birth. The vast majority of foals develop protective 4 
immune responses that operate throughout adult life, whereas affected foals develop 5 
pyogranulomatous pneumonia resembling caseous tuberculosis. Attempts to induce or 6 
accelerate protective responses in neonatal foals by vaccination have thus far been 7 
unsuccessful. We hypothesized that the immunostimulatory glycolipid α-GalCer could 8 
be used as an adjuvant to expand equine NKT cells and thereby overcome the relatively 9 
poor immune responses that are typical of newborns in virtually all species (Chappuis, 10 
1998; Flaminio et al., 2009). Importantly, a successful vaccine to prevent equine 11 
rhodococcal pneumonia will likely need to induce type 1 cellular immune responses, 12 
including IFN-γ-producing Th1 cells and R. equi-specific CTL (Breathnach et al., 2006; 13 
Harris et al., 2011; Patton et al., 2005). The CTL have been shown in our laboratory to 14 
be MHC-unrestricted and to recognize R. equi lipids, likely via the CD1 antigen-15 
presenting system. 16 
 Using data from other species, we built a detailed model of the equine CD1d 17 
molecule. Modeling showed strong homology to previously described CD1d molecules 18 
(notably human) and predicted that eqCD1d would bind α-GalCer and present it to NKT 19 
cells. Nevertheless, multiple studies, including intradermal injection of α-GalCer in vivo 20 
and in vitro CTL assays, convincingly showed no immunostimulatory effects. Moreover, 21 
α-GalCer-loaded CD1d tetramers (which have been shown to be cross-reactive in other 22 
Page 23 of 37
24 
 
species and were used to identify NKT cells in various species) did not bind equine 1 
cells, whereas they bound readily to the murine controls. 2 
There are several possible explanations for the failure of α-GalCer, α-GalCer 3 
short carbon-chain variants, and multiple α-GalCer analogues (all potent NKT cell 4 
activators in other species) to stimulate equine cells. One possibility is that none of 5 
these molecules is bound by eqCD1d. This explanation seems unlikely considering that 6 
the molecular model shows a highly conserved lipid binding groove that should be 7 
suitable for loading and presentation of α-GalCer and its variants. Nevertheless, we 8 
attempted to test this explanation using biotin-labeled α-GalCer and FACS (data not 9 
shown). In our hands, this reagent bound a broad range of equine and non-equine cells 10 
non-specifically (binding could not be blocked with unlabeled α-GalCer), raising 11 
questions about previous reports where such controls were not in place. Ultimately, we 12 
were unable to directly address this unlikely explanation.   13 
A more plausible explanation for the lack of an immunostimulatory effect in 14 
horses is that the TCR from equine NKT cells are incapable of interacting with eqCD1d 15 
and/or recognizing α-GalCer presented by eqCD1d. Although the lipid binding groove of 16 
eqCD1d has a very high homology with the huCD1d binding groove, there are 17 
substitutions that could affect the interaction of CD1d or α-GalCer-loaded CD1d with 18 
equine NKT cells. Among the 11 CD1d residues known to mediate direct contact of 19 
CD1d/α-GalCer with the NTK T cell receptor, two amino acids (huCD1d: Arg89 Gln150 20 
and muCD1d: Ser89 Asn150) were replaced (with His89 and Asp150) in eqCD1d (Borg 21 
et al., 2007). In humans, the CD1d Arg89 residue forms van der Waals contacts with the 22 
NKT-TCR CDR2 β loop and Gln150 forms a hydrogen bond with the Thr98 of the CDR3 23 
Page 24 of 37
25 
 
α loop. A previous study demonstrated that replacement of huCD1d Arg89 with His89, 1 
as found in horses, did not significantly affect the activation of human NKT cells (Zhang 2 
et al., 2009). The replacement of the CD1d Gln150 with Asp has not been tested, but 3 
aspartic acid could potentially conserve the ability to interact with the NKT-TCR loop 4 
since this residue is strongly negatively charged and typically behaves like Gln. 5 
Other residues towards the surface of the CD1d molecule near the binding 6 
groove might also influence the glycolipid head-orientation and the recognition of lipids 7 
by NKT cells (Kamada et al., 2001). Among these residues the only replacement found 8 
in eqCD1d is Met157 (huCD1d Thr157, muCD1d Thr159). Although this residue does 9 
not directly interact with α-GalCer, muCD1d Thr159 forms a conserved extra hydrogen 10 
bond with the carbonyl oxygen of galactose-modified α-GalCer analogues (Aspeslagh et 11 
al., 2011). Therefore a substitution at this site might affect the orientation of the α-12 
GalCer head and thereby alter presentation. 13 
Another possible explanation for the lack of activation of equine cells by α-GalCer 14 
is that horses may lack a T cell population homologous to human and murine NKT cells. 15 
This explanation seems unlikely considering the strong cross-species conservation of 16 
both CD1d and the NKT cell TCR α-chain. However, it is consistent with our failure to 17 
find a population of equine PBMC that bound α-GalCer loaded tetramers. An alternative 18 
interpretation of this result is that human and murine CD1d-αGalCer tetramers simply do 19 
not cross-react with equine NKT cells. Therefore, our current data do not directly 20 
address the question of whether horses have NKT cells with similar biological and 21 
functional abilities as NKT cells in other species. Likewise, it does not address the 22 
potential for expanding this population with an appropriate NKT cell agonist as part of a 23 
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novel vaccination strategy. A different agonist may be required to broadly active equine 1 
NKT cells. Alternatively, it is possible that CD1d-restricted T cells in horses are more 2 
antigen-specific (similar to CD1a, CD1b, and CD1c restricted T cells) and that horses 3 
lack a broadly reactive iNKT (Type 1 NKT cell) sub-population equivalent to what has 4 
been described.  5 
In conclusion, further studies are required to confirm the presence of an equine 6 
NKT cell and the roles played by lipid antigens in the protection against equine 7 
infectious diseases. However, this work suggests that horses are unique among 8 
previously described species and provides strong evidence that α-GalCer is unsuitable 9 
as an equine vaccine adjuvant in this species. 10 
 11 
  12 
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Fig. 1. Structural comparison of the binding domains of CD1d across species. (A-1 
D) In each image, the protein fold is shown in transparent grey cartoon format, whilst 2 
the binding groove is shown as a green wireframe structure. Each CD1d molecule is 3 
viewed on the lateral α1 side. (A) eqCD1d, (B) huCD1d, (C) boCD1d, and (D) muCD1d. 4 
(E-G) Snapshots showing the eqCD1d cavity bound to (E) huCD1d α-GalCer 5 
(C18;C26), (F) boCD1d α-GalCer (C18;C16) and (G) muCD1d OCH (α-GalCer 6 
analogue) (C9;C26). The α-GalCer (CPK wireframe format) are shown bound within the 7 
cavity (white wireframe surface). Each binding domain is viewed from the α1 side. 8 
These models predict that the eqC1d binding groove will accommodate all three α-9 
GalCer molecules. 10 
 11 
Fig. 2. Effects of α-GalCer on equine immune cells. (A, B) CTL Assays: (A) Effector 12 
cells from equine PBMCs were stimulated for 7 days with α-GalCer (grey bars) or R. 13 
equi (horizontally striped bars). Effector cells were then added to MHC mismatched 14 
target cells at a 9:1 E:T cell ratio. Target cells were either pulsed with α-GalCer 15 
(100ng/ml), infected with R. equi, or untreated (negative control). (B) Effector cells 16 
stimulated for 7 days with either R. equi (horizontally striped bars), R. equi + α-GalCer 17 
@ 100ng/ml (vertically striped bars), or media containing control vehicle (no stimulation 18 
- open bars) were added to R. equi-infected target cells at E:T ratios of 1:1, 3:1 or 9:1. 19 
In all CTL experiments, the percentage specific lysis was measured using a chromium 20 
release assay. Data shown is a representative of 3 independent experiments performed 21 
in 3 horses. An asterisk indicates significant lysis, defined as 3 standard errors above 22 
the negative control value. (C) Lymphoproliferation: Equine cells were pulsed with 23 
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media only (no stimulation - open bars), α-GalCer (grey bars), live R. equi (horizontally 1 
striped bars), R. equi lipids (ascendant striped bars) or IL-2 (black bars - positive 2 
control). Cells were also concomitantly pulsed with live R. equi plus α-GalCer (vertically 3 
striped bars) or R. equi lipids plus α-GalCer (descendent striped bars). The proliferation 4 
of equine cells using H3-Thymidine uptake was assessed after 72 hours of stimulation. 5 
Data shown (Horse #181, Horse #189, and Horse #187) are from 3 independent 6 
experiments; each value is the mean of triplicates plus standard deviation. An asterisk 7 
represents significant difference when compared with media control (p value < 0.05).  8 
 9 
Fig. 3. In vivo effects of α-GalCer in horses: Recruitment of immune cells and 10 
transcription of cytokines and cytolytic molecules as measured by quantitative 11 
RT-PCR. Adult horses were injected intradermally with saline only (open bars), α-12 
GalCer alone (grey bars), heat-killed R. equi (horizontally striped bars), heat-killed R. 13 
equi plus α-GalCer (vertically striped bars) or R. equi lipids (ascendant striped bars). 14 
mRNA expression for (A) cell markers and (B) cytokines and cytolytic molecules were 15 
detected by Real-Time PCR in biopsy samples from the injection site. Relative 16 
increase/decrease was compared to injection with saline only and results were natural 17 
log transformed to satisfy the statistic assumption. Data are from 3 animals are 18 
expressed as means plus standard error. An asterisk represents significant difference 19 
when compared with saline control (p value < 0.05).  20 
 21 
Fig. 4. Failure of CD1d-tetramers to bind an equine NKT population. Equine PBMC 22 
and murine cells were membrane-labeled with anti-CD3-Alexa488 species-specific 23 
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monoclonal antibodies (x-axis), and stained with human or murine CD1d tetramers-1 
Alexa647 (y-axis) that were either loaded with α-GalCer or empty, before (day 0) or after 2 
(day 5) stimulation with α-GalCer (100ng/ml) + IL-2. Number in gates indicates 3 
percentage of live cells that were concomitantly positive for CD3 and the tetramers. One 4 
representative case showing 1 × 106 viable cells events is shown. An asterisk indicates 5 
a significant difference when compared with the respective matching empty tetramers.  6 
 7 
Fig. 5. Effects of α-GalCer analogues and other NKT cell agonists on equine 8 
PBMC. (A) Equine PBMC and murine cells, as a positive control, were pulsed with 9 
media alone (open bars), α-GalCer (100ng/ml) containing alkyl chains ranging between 10 
eight carbons to 26 carbons (grey bars) or with IL-2 (black bars – positive control). (B) 11 
Equine PBMC and murine cells, were pulsed with media alone (open bars), α-GalCer 12 
(grey bar), the additional nine NKT cell agonists (100ng/ml), lipid control, R. equi lipids 13 
(ascendant striped bars) or IL-2 (black bars - positive control). The proliferation of cells 14 
using thymidine uptake was assessed after 72 hours of stimulation. Data shown (Horse 15 
#184, #185 and #188) are representative of 4 independent experiments performed in 4 16 
horses, and each value shows the mean of triplicates plus standard deviation. An 17 
asterisk represents significant difference when compared with media control (p value 18 
< 0.05).  19 
 20 
Table 1 NKT cell agonists tested 21 
Glycolipids Reference 
OCH  (Miyamoto et al., 2001) 
α-GalCer C20:2 (Yu et al., 2005) 
7DW8-5 (Li et al., 2010) 
Page 35 of 37
36 
 
α-GalCer C4Ph  (Chang et al., 2007) 
α-GlcCer C26 (Kinjo et al., 2006) 
α-GalDAG  (Jervis et al., 2010) 
α-ThrCer  (Silk et al., 2008) 
PBS-57 (Liu et al., 2006) 
Dimer  (Jervis et al., 2012) 
GalNHAc C20:2 PJJ 
 1 
2 
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